TY - JOUR
T1 - Clinical application of tumor immune checkpoint and chimeric antigen receptor T-cell
T2 - monotherapy and combination therapy
AU - Li, Linyu
AU - Zhang, Tingting
AU - Jia, Xiaohui
AU - Kong, Lingzhe
AU - Meng, Bin
AU - Ren, Xiubao
AU - Fu, Kai
AU - Qiang, Pan Hammarström
AU - Wang, Xianhuo
AU - Zhang, Huilai
PY - 2017/4/30
Y1 - 2017/4/30
N2 - Outstanding progress in immune checkpoint therapy has been achieved with respect to tumor therapy, which brings unprecedented hope for patients with advanced cancer. So far, four immune checkpoint inhibitors have been approved by the Food and Drug Administration (FDA) to be used in the treatment of various tumors. Meanwhile, researchers has found that chimeric antigen receptor T-cell (CART) therapy has significant anti-tumor effect on hematologic malignancies, which means that it is expected to be a potential choice for more patients with cancer. In this review, we focus on the latest advances in tumor immune checkpoint therapy and CAR-T therapy, and discuss the potential values of them used in combination in clinical application.
AB - Outstanding progress in immune checkpoint therapy has been achieved with respect to tumor therapy, which brings unprecedented hope for patients with advanced cancer. So far, four immune checkpoint inhibitors have been approved by the Food and Drug Administration (FDA) to be used in the treatment of various tumors. Meanwhile, researchers has found that chimeric antigen receptor T-cell (CART) therapy has significant anti-tumor effect on hematologic malignancies, which means that it is expected to be a potential choice for more patients with cancer. In this review, we focus on the latest advances in tumor immune checkpoint therapy and CAR-T therapy, and discuss the potential values of them used in combination in clinical application.
KW - CAR-T
KW - Combination therapy
KW - Immune checkpoint
UR - http://www.scopus.com/inward/record.url?scp=85027221219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027221219&partnerID=8YFLogxK
U2 - 10.3760/cma.j.issn.0254-5101.2017.04.014
DO - 10.3760/cma.j.issn.0254-5101.2017.04.014
M3 - Review article
AN - SCOPUS:85027221219
VL - 37
SP - 315
EP - 319
JO - Chinese Journal of Microbiology and Immunology
JF - Chinese Journal of Microbiology and Immunology
SN - 0254-5101
IS - 4
ER -